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Children in healthcare settings endure painful 
procedures daily. Venepuncture of paediatric 
participants is also becoming increasingly common 
in many research studies and surveys. Several 
researchers have stated that venepuncture procedures 
are distressing to children and their families, and may affect the ease of 
performing the procedure,[1,2] the success rate and the child-healthcare 
provider relationship. We could find no reports documenting the 
efficacy of EMLA cream in a field setting for the management of 
pain related to short procedures. Discomfort associated with these 
procedures continues to be inadequately managed.
Topical analgesia is becoming essential as the number of invasive 
screening procedures and health surveys involving children rises 
steadily. Children often do not understand why they are subjected 
to needle procedures such as phlebotomy.[2] Little is known about 
the frequency of these invasive procedures, or about the use of 
interventions to ease the pain. A eutectic mixture of local anaesthetics 
(EMLA), which consists of 2.5% lidocaine and 2.5% prilocaine, is 
a topical analgesic that works by blocking pain transmission to the 
brain. Few studies have addressed whether use of a local anaesthetic 
influences venepuncture success and hence enrolment and retention 
rates of children in research studies and surveys. This study describes 
the efficacy of EMLA cream in preventing pain in school-aged 
children in a field setting. When carried out in a reassuring 
environment, this non-invasive means of delivering analgesia is 
expected to minimise distress during venepuncture procedures. 
The implications for practice and the benefits to both researchers 
and participants are expected to result in improved public health 
screening.
Methods
This study was an ancillary investigation in a larger longitudinal 
study measuring various health indicators and psychosocial needs 
of preschool and school-aged children. As far as possible, data 
collection was integrated into the usual services at the research site. 
One hundred and eighty-four consecutive children aged 6 - 8 years 
attending for follow-up over a 4-month period were invited to join 
the current study. Another group of 20 children who did not receive 
any local analgesia was assessed as a control. EMLA application 
was limited to children requiring needle puncture of intact skin for 
phlebotomy procedures. The collected venous blood samples were 
used to assess the children’s anaemia and iron status by laboratory 
assays for haemoglobin, serum ferritin and soluble transferrin 
receptor. These results are reported in another article.[3]
Application
The EMLA cream was applied at the research site before the phlebotomy 
procedure. The cream was applied to the skin surface under occlusion 
with a Tegaderm patch (3M). The dressing was placed at least 60 
minutes before the phlebotomy procedure to allow for adequate local 
cutaneous absorption. A maximum of 120 minutes’ application time 
was allowed to avoid significant systemic absorption of the lidocaine 
and prilocaine; 1 - 2 cm3 of cream was applied per cm2 of skin, up to 
a maximum of 10 mL on the same participant. During the application 
time the children continued with other scheduled research activities. 
The cream was removed and the skin disinfected before a venous blood 
sample was collected using a 22 G Vacutainer needle. The participant 
was repeatedly asked about any skin or systemic reactions during and 
up to 2 hours after the application time.
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Outcome assessment
The primary outcome was analgesic efficacy for acute procedure-
related pain. Anticipatory anxiety, pain, adverse reactions and ease 
of procedure were assessed. A subjective visual analogue scale (VAS) 
pain score of 0 - 3 was generated by the researcher and obtained 
through direct enquiry from each participant immediately after 
the phlebotomy procedure was completed. Pain responses were 
documented by the principal investigator (TPG) using subjective 
pain scores expressed through the VAS. A wry face was assessed as 
indicating mild pain, limb withdrawal as indicating moderate pain, 
and crying or resisting the procedure as indicating severe pain. The 
children were also asked about any pain they had experienced. The 
children’s responses and the observations made by the clinician were 
both scored on a four-point verbal scale (pain-free – 0, mild pain – 1, 
moderate pain – 2, severe pain – 3). The parent or caregiver observer 
ratings for the efficacy of EMLA cream in relieving pain were also 
considered.
Statistical analysis
The SPSS Statistics for Windows package, version 22.0 (IBM, USA), 
was used for data entry and analysis. Findings from the study were 
assessed with the variables characterised as either categorical or 
continuous. Categorical variables such as parental ratings of EMLA 
efficacy and anticipatory anxiety were analysed using a two-tailed 
Fisher’s exact test. Continuous variables such as VAS provider and 
self-reported scores were assessed using Student’s t-test and graphical 
plots. The study reported on the effects of EMLA with regard to 
the mean difference in pain, anxiety and ease of procedure during 
phlebotomy between the group that received EMLA and the control 
group with no intervention, relative risk (RR), and whether the effect 
on pain reduction was significant or non-significant.
Ethical considerations
This research received ethical clearance from the official review board 
of the University of KwaZulu-Natal Biomedical Research Ethics 
Committee. Informed consent was obtained from the children’s 
caregivers before they were included in the study.
Results
One hundred and eighty-four children participated in the study. 
The participants’ ages ranged from 72 to 102 months (mean 83.65, 
standard deviation 7.32). There were 109 males (59.2%) and fewer 
females (n=75, 40.8%). The mean application time was 72 minutes 
(range 60 - 104).
Anticipatory anxiety
The children were individually counselled before application of the 
cream, and told that it would help reduce the pain. This, together 
with a reassuring environment, resulted in the children co-operating 
with the phlebotomy procedure; 24/184 (13.0%) were noted to be 
mildly anxious, although they allowed the phlebotomy procedure to 
continue. The children in the control group were generally anxious 
(12/20, 60.0%) and showed some distress despite the reassuring 
environment.
Pain and distress
EMLA cream was effective in reducing pain during phlebotomy in 
91.3% of participants compared with 25.0% in the control group. 
Of children who underwent procedures conducted with EMLA, 
only 3/184 (1.6%) complained of moderate pain and 13/184 
(7.1%) of mild discomfort. The rest (n=168, 91.3%) were without 
pain. No child reported severe pain. The researcher’s pain scores 
were significantly lower in the EMLA group than in the control 
group (p=0.000). The participants who received EMLA also self-
reported significantly lower pain scores (p=0.001). With regard to 
anaesthetic efficacy, EMLA significantly reduced the risk of pain 
compared with the control group (RR 0.11; 95% confidence interval 
(CI) 0.05 - 0.27), self-reporting of pain (RR 0.12; 95% CI 0.04 - 
0.24), and observations by the investigators of responses indicating 
pain (RR 0.13; 95% CI 0.02 - 0.22).
Adverse reactions
EMLA cream was well tolerated and non-toxic in this study 
population. No adverse dermatological or systemic reactions were 
noted, and no itching or local reactions were observed. The children 
were able to continue with other scheduled research activities during 
the application time and also after the phlebotomy procedure.
Ease of procedure
Of phlebotomies with EMLA, 172/184 (93.5%) were graded as ‘easy’ 
compared with 12/20 (60.0%) in the control group. Easier needle 
insertion was noted with EMLA cream, and this was statistically 
significant (R=0.417; p=0.000).
Parent or caregiver ratings
The ratings of EMLA cream efficacy by parent or caregiver observer 
scales were in favour of the cream. They felt that EMLA cream was 
effective in decreasing the distress associated with the phlebotomy 
procedure in 180/184 children (97.8%).
Discussion
This study found the use of EMLA cream to be an effective strategy 
for managing acute procedure-related pain in children participating 
in field surveys. EMLA also improved the ease of the procedure. The 
reduced trouble and effort associated with restraining a struggling 
child has been reported by other researchers.[4] The 33.5% increase in 
ease of drawing blood when EMLA was used (93.5% for the EMLA 
group minus 60.0% for the control group) suggests that topical 
analgesia offers a substantial benefit. The analgesic effect of EMLA 
for this study population was 91.3%, comparable to other studies 
conducted in outpatient settings.[5,6] Errors that may cause inadequate 
analgesia include inappropriate application, a short waiting time, 
using a small volume of cream, and poor occlusion strategies such as 
a loose Tegaderm dressing.[1,2] These errors were minimised in this 
study by controlling the application time to between 1 and 2 hours, 
measuring the volume of cream used, and having trained medical 
personnel apply the cream and dressing.
EMLA was well tolerated and non-toxic. No participants developed 
side-effects, although this could be due to the small sample size and/
or the short follow-up period. Although EMLA is generally reported 
to be non-toxic after infancy, local adverse outcomes have been 
described by other researchers and include erythema, oedema, 
allergic contact dermatitis and hyperpigmentation.[7] Seizures 
and respiratory depression were described in one case report.[8] 
Methaemoglobinaemia was the most dangerous and potentially fatal 
complication reported in neonates.[9]
The limitations of EMLA use observed in this study included the 
need to wait for at least 60 minutes from application of the cream 
to the venepuncture procedure. The considerable waiting time 
required before an adequate analgesic effect could be overcome 
by allowing capable children and their caregivers to participate 
in the application after being instructed in the proper use of the 
cream.[10] The application of EMLA could also be scheduled earlier, 
while the child participates in other research activities or in the 
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waiting area. It was not possible to distinguish between problematic 
venepunctures that necessitated numerous needle insertions and 
anticipatory anxiety resulting in the child struggling even when 
pain relief was adequate. Anticipatory anxiety can be expected 
to lessen with widespread use of pharmacological and non-
pharmacological strategies to reduce needle phobias.[11] If adequate 
pain relief is provided, children can be expected to become less 
fearful of needle-related procedures. The cost-effectiveness of the 
cream may be an issue if it is used in on a large scale, and needs 
to be weighed against the benefits of a stress-free, easier and safer 
venepuncture procedure.
Needle phobia is a recognised medical disorder, affecting 
approximately 10% of the world population and resulting in fear and 
avoidance behaviour.[12] In the current study, 13.0% of the children 
who received EMLA cream were anxious about the procedure 
v. 60.0% in the control group. In an era when health of children 
in underdeveloped countries is being prioritised, with large-scale 
screening and intervention initiatives, avoidance of healthcare in 
order to avoid needle experience would be unfortunate.[12] Many 
screening tests and interventions rely on the hypodermic needle. 
Health professionals need to be mindful of the fact that needle phobia, 
although infrequent, may lead to avoidance of health initiatives. The 
use of topical analgesia in children should be prioritised, and health 
professionals need to be aware of available options to prevent the pain 
associated with needle procedures.
The use of EMLA cream can be expected to result in safer and 
more effective venepuncture procedures in children by lessening the 
discomfort experienced by the child and making it easier to perform 
these procedures. Numerous other non-invasive topical anaesthetic 
options are available that can be measured against EMLA. Well-
designed clinical trials are necessary in order to assess EMLA further 
with regard to relative efficacy, safety and feasibility in children in a 
large-scale field setting in national surveys and also for childhood 
immunisations. Further studies, such as case-control studies, are also 
necessary to determine whether a waiting time of <60 minutes can be 
used without compromising the efficacy of the cream.
Conclusion
Use of EMLA cream can reduce pain, make venepuncture easier, 
and improve the therapeutic relationship with health professionals. 
Further research is recommended to assess whether EMLA can be 
used for childhood immunisations.
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